Investigation and analysis of diagnosis and treatment of cancer patients in prefectural hospitals from Sichuan province during 2019 novel coronavirus disease (COVID-19) epidemic
Fan Yixin1, Li Zhihui2, Chen Ailin1, Huang Rui1, Yin Li1, Zhang Peng1
1Department of Radiation Oncology Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu 610041, China; 2Department of Radiation Oncology, Western Theater General Hospital, Chengdu 610083, China
Abstract：Objective To investigate the diagnosis and treatment of cancer patients in the prefectural and municipal hospitals in Sichuan province during the outbreak of 2019 novel coronavirus disease (COVID-19) epidemic, and analyze the impact of the epidemic on the hospitalization and treatment of cancer patients, aiming to provide reference for the diagnosis and treatment of cancer patients by medical institutions in different provinces. Methods The prefectural and municipal hospitals in Sichuan province were investigated in the form of questionnaire. Results A survey was conducted in 37 prefecture-level large and medium-sized hospitals in Sichuan province, of which Grade 3A hospitals accounted for 78.4%. Among the investigated hospitals, the hospitals whose hospitalization index of oncology patients and radiotherapy index of radiotherapy patients were< 1 after the first-class response were 83.7% and 93.1%, respectively. Hospitals with normal or delayed chemotherapy within one-week consisted of 54.1%, and 89.7% of the hospitals received normal radiotherapy or delayed radiotherapy within one-week after the Spring Festival. After the second-class response, the proportion of hospitals with oncology patients and radiotherapy patients that increased after the first-class response was 78.4% and 79.3%, respectively. Conclusions Under the guidance of the State Council, the Sichuan Provincial Party Committee and the Provincial Government, Health Commission of Sichuan Province, and the municipal health commissions at various levels and under the joint efforts of medical institutions and front-line medical staff from Department of Oncology, a majority of cancer patients admitted to prefectural and municipal hospitals in Sichuan province can receive active and effective treatment during the outbreak of COVID-19 epidemic.
Fan Yixin,Li Zhihui,Chen Ailin et al. Investigation and analysis of diagnosis and treatment of cancer patients in prefectural hospitals from Sichuan province during 2019 novel coronavirus disease (COVID-19) epidemic[J]. Chinese Journal of Radiation Oncology, 2020, 29(6): 407-410.
[1] 世界卫生组织. 世卫组织总干事2020年3月11日在2019冠状病毒病(COVID-19)疫情媒体通报会上的讲话[EB/OL][2020-03-11].https://www.bilibili.com/read/cv5080676/. [2] 中华人民共和国国家卫生健康委员会. 全力做好新型冠状病毒肺炎疫情防控工作2020年3月12日新闻发布会文字实录[EB/OL][2020-03-12].http://www.nhc.gov.cn/xcs/yqfkdt/202003/9df571ff7f144bc69f63bbb636fe2b2d.shtml. [3] 中华人民共和国国家卫生健康委员会公告. 疾病预防控制局. 新型冠状病毒感染的肺炎纳入法定传染病管理.[EB/OL][2020-01-20].http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8df3f6701d49f33.shtml. [4] 四川省应急管理. 四川启动突发公共卫生事件Ⅰ级应急响应[EB/OL][2020-01-24]. http://www.sc.gov.cn/10462/10464/10797/2020/1/24/3ff65fa2d2054f78b7c551c7ee961167.shtml. [5] 四川省人民政府四川省应急委员会. 四川省应急委员会关于将COVID-19疫情防控一级响应调整为二级响应的决定[EB/OL][2020-02-25].http://www.sc.gov.cn/10462/10464/10727/10866/2020/2/25/1b3d9ff5ed3844349c7fdc1bc1a0edcf.shtml. [6] 四川省卫生健康委员会. 我省新型冠状病毒肺炎疫情最新情况(3月12日发布)[EB/OL][2020-03-12].http://wsjkw.sc.gov.cn/scwsjkw/gzbd01/2020/3/12/12124dfd43414b61a24a034f35730a9e.shtml. [7] 苗静.2010-2014年某院住院人次季节变化分析[J]. 中国卫生统计,2016,33(3):503-504.Miao J. Seasonal change analysis of inpatients in a hospital from 2010 to 2014[J]. Chin J Health Statist, 2016, 33(3):503-504. [8] 王希方,秦思达,白俊,等. 新型冠状病毒肺炎疫情期间肺癌患者的应对措施[J]. 现代肿瘤医学,2020,28(10):1804-1807. DOI:10.3969/j.issn.1672-4992.2020.10.044. Wang XF, Qin SD, Bai J, et al. Countermeasures on the COVID-19 in lung cancer patients[J]. J Mod Oncol, 2020,28(10):1804-1807. DOI:10.3969/j.issn.1672-4992.2020.10.044. [9] 杨振宇, 谭凯, 杜锡林,等. 新型冠状病毒疫情期间肿瘤患者的应急管理及防护措施[J]. 现代肿瘤医学, 2020, 28(6):1053-1055. DOI:10.3969/j.issn.1672-4992.2020.06.042. Yang ZY, Tan K, Du XL, et al. Emergency management and protection measures for tumor patients during new coronavirus eprdemic[J]. J Mod Oncol, 2020, 28(6):1053-1055. DOI:10.3969/j.issn.1672-4992.2020.06.042. [10] 王卫东,冯梅,郎锦义.新型冠状病毒肺炎疫期肿瘤患者防控的挑战与对策[J]. 肿瘤预防与治疗,2020,33(2):87-90. Wang WD, Feng M, Lang JY. Challenges and strategies for prevention and control of Corona Virus Disease 2019 in cancer patients[J]. J Cancer Control Treat, 2020, 33(2):87-90. [11] 张惠姗,王捷忠,张伟,等. 局部晚期非小细胞肺癌患者放化疗的预后相关因素分析[J]. 福建医科大学学报,2019,53(4):235-240. Zhang HS, Wang JZ, Zhang W, et al. Prognostic factors of radiotherapy and chemotherapy in patients with LA-NSCLC[J]. J Fujian Med Univers,2019,53(4):235-240. [12] 四川省卫生健康委员会. 转发《关于进一步落实科学防治精准施策分区分级要求做好疫情期间医疗服务管理工作的通知》的通知[EB/OL][2020-02-27].http://wsjkw.sc.gov.cn/scwsjkw/zcwj11/2020/2/27/9d66c2041b08401f9e25d7869c84d099.shtml. [13] 史艳侠,邢镨元,张俊,等. 肿瘤化疗导致的中性粒细胞减少诊治专家共识(2019年版)[J]. 中国医学前沿杂志(电子版),2019,11(12):86-92. Shi YX, Xing PY, Zhang J, et al. Consensus on the clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2019 edition)[J] Chin J Front Med Sci (Elect Ver), 2019, 11(12):86-92. [14] 张婷婷,张丽燕,国仁秀. PD-1抑制剂治疗消化道肿瘤中免疫相关不良事件的护理[J]. 肿瘤综合治疗电子杂志, 2019,5(1):111-114. DOI:10.12151/JMCM.2019.01-13. Zhang TT, Zhang YL, Guo RX. Nursing care of immune-related adverse events in patients with gastrointestinal cancer treated with PD-1 inhibitor[J]. J Mul Cancer Manag (Elect Ver), 2019,5(1):111-114. DOI:10.12151/JMCM.2019.01-13.
2020, Vol. 29 
